Safety and efficacy of Paxlovid in the treatment of adults with mild to moderate COVID-19 during the omicron epidemic: a multicentre study from China

References

• Li J, Huang DQ, Zou B, et al. Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol. 2021;93(3):1449–1458. doi: 10.1002/jmv.26424
   PubMed Web of Science ®Google Scholar
• Atzrodt CL, Maknojia I, McCarthy RDP, et al. A guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2. FEBS J. 2020;287(17):3633–3650. doi: 10.1111/febs.15375
   PubMed Web of Science ®Google Scholar
• Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for disease control and prevention. JAMA. 2020;323(13):1239–1242. doi: 10.1001/jama.2020.2648
   PubMed Web of Science ®Google Scholar
• Fernandes Q, Inchakalody VP, Merhi M, et al. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Ann Med. 2022;54(1):524–540. doi: 10.1080/07853890.2022.2031274
   PubMed Web of Science ®Google Scholar
• Hu Y, Lewandowski EM, Tan H, et al. Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir. ACS Cent Sci. 2023;9(8):1658–1669. doi: 10.1021/acscentsci.3c00538
   PubMedGoogle Scholar
• Stevens LJ, Pruijssers AJ, Lee HW, et al. Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms. Sci Transl Med. 2022;14(656):eabo0718. doi: 10.1126/scitranslmed.abo0718
   PubMed Web of Science ®Google Scholar
• Sacco MD, Hu Y, Gongora MV, et al. The P132H mutation in the main protease of omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition. Cell Res. 2022;32(5):498–500. doi: 10.1038/s41422-022-00640-y
   PubMed Web of Science ®Google Scholar
• Zuckerman NS, Bucris E, Keidar-Friedman D, et al. Nirmatrelvir resistance - de novo E166V/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir/ritonavir monotherapy leading to clinical and virological treatment failure - a case report. Clin Infect Dis. 2023;ciad494. doi: 10.1093/cid/ciad494
   PubMed Web of Science ®Google Scholar
• Malik JA, Ahmed S, Mir A, et al. The SARS-CoV-2 mutations versus vaccine effectiveness: new opportunities to new challenges. J Infect Public Health. 2022;15(2):228–240. doi: 10.1016/j.jiph.2021.12.014
   PubMed Web of Science ®Google Scholar
• Wang Z, Yang L. The therapeutic potential of natural dietary flavonoids against SARS-CoV-2 infection. Nutrients. 2023;15(15):3443–3459. doi: 10.3390/nu15153443
   PubMed Web of Science ®Google Scholar
• Fan Y, Li X, Zhang L, et al. SARS-CoV-2 omicron variant: recent progress and future perspectives. Signal Transduct Ther. 2022;7(1):141–151. doi: 10.1038/s41392-022-00997-x
   PubMed Web of Science ®Google Scholar
• Vitiello A, Ferrara F, Auti AM, et al. Advances in the omicron variant development. J Intern Med. 2022;292(1):81–90. doi: 10.1111/joim.13478
   PubMed Web of Science ®Google Scholar
• Chekol AE, Tiruneh G/Medhin M, Behaile T/Mariam A, et al. Impacts and potential preventive strategies of omicron SARS-CoV-2 variant infection. IDR. 2022;15:1871–1887. doi: 10.2147/IDR.S360103
   Google Scholar
• Callaway E. Heavily mutated omicron variant puts scientists on alert. Nature. 2021;600(7887):21–26. doi: 10.1038/d41586-021-03552-w
   PubMed Web of Science ®Google Scholar
• Zhang J, Xiao T, Cai Y, et al. Structure of SARS-CoV-2 spike protein. Curr Opin Virol. 2021;50:173–182. doi: 10.1016/j.coviro.2021.08.010
   PubMed Web of Science ®Google Scholar
• Zhang L, Jackson CB, Mou H, et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun. 2020;11(1):6013–6021. doi: 10.1038/s41467-020-19808-4
   PubMed Web of Science ®Google Scholar
• Huang S, Gao Z, Wang S. China’s COVID-19 reopening measures-warriors and weapons. Lancet (London, England). 2023;401(10377):643–644. doi: 10.1016/S0140-6736(23)00213-1
   PubMed Web of Science ®Google Scholar
• Halford B. The path to Paxlovid. ACS Cent Sci. 2022;8(4):405–407. doi: 10.1021/acscentsci.2c00369
   PubMed Web of Science ®Google Scholar
• Joyce RP, Hu VW, Wang J. The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations. Med Chem Res. 2022;31(10):1637–1646. doi: 10.1007/s00044-022-02951-6
   PubMed Web of Science ®Google Scholar
• Wang Z, Yang L. In the age of omicron variant: Paxlovid raises new hopes of COVID-19 recovery. J Med Virol. 2022;94(5):1766–1767. doi: 10.1002/jmv.27540
   PubMed Web of Science ®Google Scholar
• Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. N Engl J Med. 2022;386(15):1397–1408. doi: 10.1056/NEJMoa2118542
   PubMed Web of Science ®Google Scholar
• Amani B, Amani B. Efficacy and safety of nirmatrelvir/ritonavir (paxlovid) for COVID-19: a rapid review and meta-analysis. J med virol. 2023;95(2):e28441. doi: 10.1002/jmv.28441
   PubMed Web of Science ®Google Scholar
• Hung YP, Lee JC, Chiu CW, et al. Oral nirmatrelvir/ritonavir therapy for COVID-19: the dawn in the dark? Antibiotics. 2022;11(2):220–226. doi: 10.3390/antibiotics11020220
   Google Scholar
• Malden DE, Hong V, Lewin BJ, et al. Hospitalization and emergency department encounters for COVID-19 after paxlovid treatment — California, December 2021–May 2022. MMWR Morb Mortal Wkly Rep. 2022;71(25):830–833. doi: 10.15585/mmwr.mm7125e2
   PubMed Web of Science ®Google Scholar
• Ioannidis JPA, Zonta F, Levitt M. Estimates of COVID-19 deaths in Mainland China after abandoning zero COVID policy. Eur J Clin Invest. 2023;53(4):e13956. doi: 10.1111/eci.13956
   PubMed Web of Science ®Google Scholar
• Yang L, Wang Z. Bench-to-bedside: innovation of small molecule anti-SARS-CoV-2 drugs in China. Eur J Med Chem. 2023;257:e115503. doi: 10.1016/j.ejmech.2023.115503
   PubMed Web of Science ®Google Scholar
• Zhong W, Jiang X, Yang X, et al. The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: results of a non-randomized clinical trial. Front Med. 2022;9:e980002. doi: 10.3389/fmed.2022.980002
   Google Scholar
• Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin Infect Dis. 2023;76(3):342–349. doi: 10.1093/cid/ciac443
   PubMed Web of Science ®Google Scholar
• Weng C, Xie R, Han G, et al. Safety and efficacy of Paxlovid against omicron variants of coronavirus disease 2019 in elderly patients. Infect Dis Ther. 2023;12(2):649–662. doi: 10.1007/s40121-023-00760-x
   PubMed Web of Science ®Google Scholar
• Wang C, Liu B, Zhang S, et al. Differences in incidence and fatality of COVID-19 by SARS-CoV-2 omicron variant versus Delta variant in relation to vaccine coverage: a world-wide review. J Med Virol. 2023;95(1):e28118. doi: 10.1002/jmv.28118
   PubMed Web of Science ®Google Scholar
• Wang L, Møhlenberg M, Wang P, et al. Immune evasion of neutralizing antibodies by SARS-CoV-2 omicron. Cytokine Growth Factor Rev. 2023;70:13–25. doi: 10.1016/j.cytogfr.2023.03.001
   PubMed Web of Science ®Google Scholar
• Christensen PA, Olsen RJ, Long SW, et al. Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with coronavirus disease 2019 caused by the omicron variant of severe acute respiratory syndrome coronavirus 2 in Houston, Texas. Am J Pathol. 2022;192(4):642–652. doi: 10.1016/j.ajpath.2022.01.007
   PubMed Web of Science ®Google Scholar
• Chilamakuri R, Agarwal S. COVID-19: characteristics and therapeutics. Cells. 2021;10(2):206–234. doi: 10.3390/cells10020206
   PubMed Web of Science ®Google Scholar
• Huang G, Kovalic AJ, Graber CJ. Prognostic value of leukocytosis and lymphopenia for coronavirus disease severity. Emerg Infect Dis. 2020;26(8):1839–1841. doi: 10.3201/eid2608.201160
   PubMed Web of Science ®Google Scholar
• Oudkerk M, HR B, Kuijpers D, et al. d-Dimer and COVID-19. Radiology. 2020;297(3):343–344. doi: 10.1148/radiol.2020203481
   Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England). 2020;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3
   PubMed Web of Science ®Google Scholar
• Mahase E. Covid-19: pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. Clin Res 2021; 375: 2713–2714. BMJ.
   Google Scholar
• Shah MM, Joyce B, Plumb ID, et al. Paxlovid associated with decreased hospitalization rate among adults with COVID-19 — United States, April–September 2022. MMWR Morb Mortal Wkly Rep. 2022;71(48):1531–1537. doi: 10.15585/mmwr.mm7148e2
   PubMed Web of Science ®Google Scholar
• Amani B, Akbarzadeh A, Amani B, et al. Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID-19: a systematic review and meta-analysis. J Med Virol. 2023;95(6):e28889. doi: 10.1002/jmv.28889
   PubMed Web of Science ®Google Scholar
• Jing Y, Diao L, Han L. Adverse events associated with potential drugs for COVID-19: a case study from real-world data. Brief Bioinform. 2021;22(2):1232–1238. doi: 10.1093/bib/bbaa234
   PubMed Web of Science ®Google Scholar
• Wei C, Liu Y, Liu Y, et al. Clinical characteristics and manifestations in older patients with COVID-19. BMC Geriatr. 2020;20(1):395–403. doi: 10.1186/s12877-020-01811-5
   PubMed Web of Science ®Google Scholar
• Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):e2000547. doi: 10.1183/13993003.00547-2020
   PubMed Web of Science ®Google Scholar
• Wagner C, Griesel M, Mikolajewska A, et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev. 2021;8(8):e14963. doi: 10.1002/14651858.CD014963
   Google Scholar
• Pinzón MA, Ortiz S, Holguín H, et al. Dexamethasone vs methylprednisolone high dose for covid-19 pneumonia. PLoS One. 2021;16(5):e252057. doi: 10.1371/journal.pone.0252057
   PubMed Web of Science ®Google Scholar
• Rüthrich MM, Giessen-Jung C, Borgmann S, et al. COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry. Ann Hematol. 2021;100(2):383–393. doi: 10.1007/s00277-020-04328-4
   PubMed Web of Science ®Google Scholar
• Akirov A, Masri-Iraqi H, Atamna A, et al. Low Albumin Levels are Associated with mortality risk in hospitalized patients. Am J Med. 2017;130(12):1411–1465. doi: 10.1016/j.amjmed.2017.07.020
   Web of Science ®Google Scholar
• Aziz M, Fatima R, Lee-Smith W, et al. The association of low serum albumin level with severe COVID-19: a systematic review and meta-analysis. Crit Care. 2020;24(1):255–258. doi: 10.1186/s13054-020-02995-3
   PubMed Web of Science ®Google Scholar
• Hadid T, Kafri Z, Al-Katib A. Coagulation and anticoagulation in COVID-19. Blood Rev. 2021;47:e100761. doi: 10.1016/j.blre.2020.100761
   PubMed Web of Science ®Google Scholar
• Wool GD, Miller JL. The impact of COVID-19 disease on platelets and coagulation. Pathobiol: J Immunopathol Mol Cell Biol. 2021;88(1):15–27. doi: 10.1159/000512007
   Google Scholar